Kwok‐Kin Wong

72.7k total citations · 14 hit papers
277 papers, 28.9k citations indexed

About

Kwok‐Kin Wong is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kwok‐Kin Wong has authored 277 papers receiving a total of 28.9k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Molecular Biology, 140 papers in Oncology and 101 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kwok‐Kin Wong's work include Lung Cancer Treatments and Mutations (76 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Genomics and Diagnostics (32 papers). Kwok‐Kin Wong is often cited by papers focused on Lung Cancer Treatments and Mutations (76 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Genomics and Diagnostics (32 papers). Kwok‐Kin Wong collaborates with scholars based in United States, China and Japan. Kwok‐Kin Wong's co-authors include Peter S. Hammerman, Carla F. Kim, Matthew Meyerson, Christine M. Fillmore, Chen Zhao, Michael J. Eck, Danan Li, Jeffrey A. Engelman, Cai‐Hong Yun and Heidi Greulich and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Kwok‐Kin Wong

269 papers receiving 28.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

2010 1.8k citations Sreenath V. Sharma, Diana Lee et al. Cell profile →
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

2008 1.6k citations Kwok‐Kin Wong, Matthew Meyerson et al. profile →
Non-small-cell lung cancers: a heterogeneous set of diseases

2014 1.4k citations Peter S. Hammerman, Kwok‐Kin Wong et al. profile →
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

2013 1.1k citations Gang Lu, Richard E. Middleton et al. Science profile →
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

2009 785 citations Liang Chen, Danan Li et al. profile →
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

2009 779 citations Danan Li, Kwok‐Kin Wong et al. Cell profile →
The dTAG system for immediate and target-specific protein degradation

2018 652 citations Annan Yang, Jun Qi et al. profile →
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

2007 598 citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research profile →
Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth

2010 597 citations Hongbin Ji, Kwok‐Kin Wong et al. profile →
mRNA circularization by METTL3–eIF3h enhances translation and promotes oncogenesis

2018 567 citations Kwok‐Kin Wong et al. profile →
CT Angiography Clot Burden Score and Collateral Score: Correlation with Clinical and Radiologic Outcomes in Acute Middle Cerebral Artery Infarct

2009 504 citations Kwok‐Kin Wong et al. profile →
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

2014 451 citations Abigail Altabef, Kwok‐Kin Wong et al. Cell profile →
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

2017 361 citations Peter S. Hammerman, Kwok‐Kin Wong et al. profile →
The current state of the art and future trends in RAS-targeted cancer therapies

2022 293 citations Kwok‐Kin Wong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kwok‐Kin Wong United States	87	17.7k	11.0k	8.0k	5.8k	2.8k	277	28.9k
Jeremy A. Squire Canada	79	18.5k 1.0×	13.3k 1.2×	8.1k 1.0×	8.6k 1.5×	2.2k 0.8×	382	33.7k
Hiroyuki Aburatani Japan	98	24.4k 1.4×	8.4k 0.8×	6.1k 0.8×	7.6k 1.3×	4.0k 1.4×	531	38.1k
Ravi Salgia United States	90	12.5k 0.7×	10.6k 1.0×	8.4k 1.1×	3.7k 0.6×	3.0k 1.1×	626	27.5k
Erik Larsson Sweden	56	21.9k 1.2×	8.3k 0.8×	6.9k 0.9×	9.7k 1.7×	3.7k 1.3×	208	34.1k
Daniel J. Hicklin United States	91	20.8k 1.2×	14.0k 1.3×	5.6k 0.7×	8.8k 1.5×	4.9k 1.8×	185	35.4k
Waun Ki Hong United States	98	16.8k 0.9×	12.7k 1.2×	8.1k 1.0×	5.5k 1.0×	1.9k 0.7×	512	34.0k
Carlos L. Arteaga United States	101	19.8k 1.1×	18.4k 1.7×	7.2k 0.9×	6.4k 1.1×	2.2k 0.8×	432	34.7k
Ming‐Sound Tsao Canada	98	16.5k 0.9×	15.3k 1.4×	13.8k 1.7×	8.3k 1.4×	2.9k 1.0×	653	37.2k
Henry S. Friedman United States	95	15.0k 0.8×	9.0k 0.8×	7.9k 1.0×	7.5k 1.3×	4.2k 1.5×	567	38.4k
Jeremy N. Rich United States	97	20.6k 1.2×	14.1k 1.3×	4.0k 0.5×	12.0k 2.1×	3.9k 1.4×	314	38.3k

Countries citing papers authored by Kwok‐Kin Wong

Since Specialization

Citations

This map shows the geographic impact of Kwok‐Kin Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kwok‐Kin Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kwok‐Kin Wong more than expected).

Fields of papers citing papers by Kwok‐Kin Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kwok‐Kin Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kwok‐Kin Wong. The network helps show where Kwok‐Kin Wong may publish in the future.

Co-authorship network of co-authors of Kwok‐Kin Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Kwok‐Kin Wong. A scholar is included among the top collaborators of Kwok‐Kin Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kwok‐Kin Wong. Kwok‐Kin Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vasudevaraja, Varshini, Kristen Labbe, Jonathan Serrano, et al.. (2022). DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome. Clinical Cancer Research. 28(17). 3824–3835. 18 indexed citations

Yang, Annan, Grit S. Herter-Sprie, Haikuo Zhang, et al.. (2018). Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discovery. 8(3). 276–287. 240 indexed citations

Liu, Yan, Yuyang Li, Xiaoen Wang, et al.. (2017). Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Research. 77(18). 5068–5076. 25 indexed citations

Hai, Josephine, Shengwu Liu, Lauren E. Bufe, et al.. (2017). Synergy of WEE1 and mTOR Inhibition in Mutant KRAS -Driven Lung Cancers. Clinical Cancer Research. 23(22). 6993–7005. 28 indexed citations

Cassano, Paolo, Éric Bui, Andrew H. Rogers, et al.. (2016). Inflammatory cytokines in major depressive disorder: A case–control study. Australian & New Zealand Journal of Psychiatry. 51(1). 23–31. 63 indexed citations

Xu, Chunxiao, Kevin A. Buczkowski, Hajime Asahina, et al.. (2015). NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics. 14(10). 2382–2389. 24 indexed citations

Soucheray, Margaret, Marzia Capelletti, Yanan Kuang, et al.. (2015). Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research. 75(20). 4372–4383. 103 indexed citations

Weisberg, Ellen, Atsushi Nonami, Chen Zhao, et al.. (2014). Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. Clinical Cancer Research. 20(21). 5483–5495. 14 indexed citations

Tchaicha, Jeremy H., Esra A. Akbay, Abigail Altabef, et al.. (2014). Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC. Cancer Research. 74(17). 4676–4684. 30 indexed citations

10.

Alagesan, Brinda, Gianmarco Contino, Alexander R. Guimarães, et al.. (2014). Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research. 21(2). 396–404. 103 indexed citations

11.

Hata, Aaron N., Alan T. Yeo, Anthony C. Faber, et al.. (2014). Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research. 74(11). 3146–3156. 60 indexed citations

12.

Chen, Zhao, Esra A. Akbay, Oliver R. Mikse, et al.. (2013). Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK -Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. Clinical Cancer Research. 20(5). 1204–1211. 51 indexed citations

13.

Beauchamp, Ellen M., Brittany A. Woods, Austin Dulak, et al.. (2013). Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss. Molecular Cancer Therapeutics. 13(2). 475–482. 44 indexed citations

14.

Lu, Gang, Richard E. Middleton, Huahang Sun, et al.. (2013). The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 343(6168). 305–309. 1108 indexed citations breakdown →

15.

Shimamura, Takeshi, Zhao Chen, Margaret Soucheray, et al.. (2013). Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6183–6192. 158 indexed citations

16.

Feng, Yan, Ye Wang, Zuoyun Wang, et al.. (2012). The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss. Cancer Research. 72(24). 6502–6511. 44 indexed citations

17.

Sharma, Sreenath V., Diana Lee, Bihua Li, et al.. (2010). A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell. 141(1). 69–80. 1828 indexed citations breakdown →

18.

Wong, Kwok‐Kin, Tyler Jacks, & Glenn Dranoff. (2010). NF-κB Fans the Flames of Lung Carcinogenesis. Cancer Prevention Research. 3(4). 403–405. 25 indexed citations

19.

Gandhi, Leena, Kate L. McNamara, Danan Li, et al.. (2009). Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. Cancer Prevention Research. 2(4). 330–337. 30 indexed citations

20.

Engelman, Jeffrey A., Kreshnik Zejnullahu, Eugene Lifshits, et al.. (2007). PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib. Cancer Research. 67(24). 11924–11932. 598 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact